Notice of intent to solicit and negotiate a non-competitive modification for PCV 15 vaccine (VAXNEUVANCE)

CDC awarded modification no. 00004 to contract no. 75D30121D11354 to Merck Sharp & Dohme Corp. (“Merck”), 2000 Galloping Hill Rd, Kenilworth, NJ 07033-1310 on January 5, 2022, in the amount of $7,495,000.00.

This notices makes available a justification and approval for other than full and open competition (JOFOC) that applies to this contract.

This contract was awarded under the authority of FAR 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements.

This modification was made to a contract part of CDC’s 2021 Vaccines For Adults (VFA) indefinite-delivery indefinite-quantity contracts. This contract provides for the purchase of standard commercial adult vaccines for the National Center for Immunization and Respiratory Diseases’ (NCIRD) immunization awardees (the fifty state health departments, several large city program and current and former U.S. Territories) to support immunization programs as provided under Section 317(j) of the Public Health Service Act and Section 13631of the Omnibus Budget Reconciliation Act of 1993.

The purpose of this modification is to add the Pneumococcal 15-valent Conjugate Vaccine (PCV 15) VAXNEUVANCE™ to the contract following the Advisory Committee on Immunization Practices (ACIP) approval and CDC recommendation in October 2021.

Merck was determined to be the only responsible source because Merck is the only manufacturer with an FDA-approved license for PCV 15 at this time.

The attached JOFOC is being made available within 14 days of the contract award in accordance with FAR 6.305(a) and will remain active for 30 days in accordance with FAR 6.305(d)(3).